IDH1 and myelodysplastic syndrome: Our data suggest that the use of NGS to monitor MRD based on IDH1/2 mutations is feasible and effective, as this method enabled us to predict relapse in the majority of patients, with an area under the curve of 0,7971 (95% CI: 0,6693 – 0,9250), and a success rate of 100% if we include the patient who developed MDS.